前列腺切除术后生化复发挽救放疗:剂量强化与常规剂量的长期随机对照试验
SAKK 09/10 是一项III期随机试验,将前列腺切除术后生化进展的男性随机分配至常规剂量(64 Gy)或剂量强化(70 Gy)的前列腺床挽救放疗(SRT),均未联合激素治疗。中位随访8.6年后,两组中位无生化进展生存(FFBP)均为8.7年(log-rank p=0.87,HR 1.03,95%CI 0.75-1.41),剂量强化SRT未优于常规剂量,但晚期≥2级胃肠道毒性更高(p=0.015)。
要点
- 剂量强化SRT(70 Gy)未改善无生化进展生存、临床PFS、激素治疗时间或OS。
- 70 Gy组晚期≥2级胃肠道毒性发生率显著高于64 Gy组(p=0.015)。
- 前列腺切除术后生化复发SRT推荐常规剂量64 Gy,无需剂量强化。
核心结论
- 长期随访显示剂量强化SRT(70 Gy)不优于常规剂量SRT(64 Gy),且晚期≥2级胃肠道毒性更高。
研究设计与样本
- SAKK 09/10为III期随机试验,2011年2月至2014年4月纳入350例前列腺切除术后生化进展患者,随机分配至64 Gy或70 Gy前列腺床SRT(各175例),均未联合激素治疗。
主要发现
- 中位随访8.6年,64 Gy组中位FFBP为8.7年(95%CI 7.1-NR),70 Gy组为8.7年(95%CI 6.7-NR),log-rank p=0.87,HR 1.03(95%CI 0.75-1.41)。
- 两组临床PFS、至激素治疗时间和OS均无显著差异。
- 晚期泌尿生殖毒性两组无显著差异,但晚期≥2级胃肠道毒性70 Gy组更常见(p=0.015)。
关键数值与推荐
- 随机时中位PSA为0.3 ng/ml。
- 主要终点为无生化进展生存(FFBP)。
- 剂量强化SRT未改善FFBP,HR 1.03(95%CI 0.75-1.41),p=0.87。
临床怎么用
- 前列腺切除术后生化复发患者行挽救放疗时,常规剂量64 Gy即可,无需剂量强化至70 Gy。
- 剂量强化至70 Gy会增加晚期≥2级胃肠道毒性风险,选择剂量时应权衡毒性。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We report long-term outcomes from the phase 3 SAKK 09/10 trial that randomly assigned men with biochemical progression after radical prostatectomy to conventional-dose (64 Gy) or dose-intensified (70 Gy) salvage radiotherapy (SRT) to the prostate bed without hormonal therapy. The primary endpoint was freedom from biochemical progression (FFBP). Secondary endpoints included clinical progression-free survival (PFS), time to hormonal treatment, overall survival (OS), and late toxicity. Between February 2011 and April 2014, 350 patients were randomly assigned (175 per arm). Median prostate-specific antigen (PSA) at randomization was 0.3 ng/ml. After median follow-up of 8.6 yr, median FFBP was 8.7 yr (95% confidence interval [CI] 7.1-not reached [NR]) after 64 Gy and 8.7 yr (95% CI 6.7-NR) after 70 Gy (log-rank p = 0.87), with a hazard ratio of 1.03 (95% CI 0.75-1.41). There was no significant difference in clinical PFS, time to hormonal treatment, or OS. While late genitourinary toxicity did not significantly differ between the arms, late grade 2 and 3 gastrointestinal toxicity was more frequent with 70 Gy (p = 0.015). After long-term follow-up dose-intensified SRT was not superior to conventional-dose SRT, but was associated with a higher rate of late grade ≥2 gastrointestinal toxicity. PATIENT SUMMARY: The optimal radiotherapy dose for patients who have higher levels of tumor markers after surgery for prostate cancer is unclear. Our long-term follow-up confirms that a higher dose only increases the chances of gastrointestinal side effects without providing any benefits to the patient. This trial is registered on ClinicalTrials.gov as NCT01272050.
引用
- Ghadjar P, Hayoz S, Zwahlen DR, et al. Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: Long-term Data from the SAKK 09/10 Randomised Phase 3 Trial. Eur Urol. 2026. PMID: 41494929. doi:10.1016/j.eururo.2025.12.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。